SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

GSK3 Inhibitor XIII

Item No. 21190

CAS Registry No.:	404828-08-6
Formal Name:	5,6,7,8-tetrahydro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-4-quinazolinamine
Synonyms:	Glycogen Synthase Kinase 3 Inhibitor XIII
MF:	$C_{18}H_{19}N_5$
FW:	305.4
Purity:	≥98%
UV/Vis.:	λ_{max}: 210, 249, 331 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GSK3 Inhibitor XIII is supplied as a crystalline solid. A stock solution may be made by dissolving the GSK3 inhibitor XIII in the solvent of choice. GSK3 Inhibitor XIII is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of GSK3 inhibitor XIII in these solvents is approximately 0.15 and 0.25 mg/ml, respectively.

Description

GSK3 Inhibitor XIII is an aminopyrazole ATP-competitive inhibitor of GSK3, with 34% inhibition when used at a concentration of 2.5 µM.[1] It inhibits androgen receptor transactivation in 22Rv1, LNCaP, and LNCaP-SSR cell lines in a dose-dependent manner. It promotes nuclear export of the androgen receptor and decreases translocation to the nucleus in PC3 and PCa prostate cancer cells, respectively.[1,2] In HEK293 cells expressing the rat $Na_v1.2$ channel, pretreatment with GSK3 inhibitor XIII dose-dependently potentiates peak current densities.[3]

References

1. Rinnab, L., Schütz, S.V., Diesch, J., *et al.* Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: Are GSK inhibitors therapeutically useful? *Neoplasia* **10(6)**, 624-634 (2008).
2. Schütz, S.V., Cronauer, M.V., and Rinnab, L. Inhibition of glycogen synthase kinase-3β promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines. *J. Cell. Biochem.* **109(6)**, 1192-1200 (2010).
3. James, T.F., Nenov, M.N., Wildburger, N.C., *et al.* The $Na_v1.2$ channel is regulated by GSK3. *Biochim. Biophys. Acta* **1850(4)**, 832-844 (2015).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM